BDO provided financial due diligence to CNX Therapeutics on their acquisition of four cancer support therapies from Clinigen, a global pharmaceutical services company.
CNX Therapeutics has acquired four medicines; Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol® (amifostine), all of which help mitigate the side effects patients may experience when treated with other cancer therapies.
The acquisition of these products represents a significant addition to CNX Therapeutics’ diverse portfolio of critical hospital products. The well-established products are marketed in more than 40 countries which brings expansion to CNX Therapeutics’ global portfolio, complementing their market presence across Europe and bringing new opportunities in Asia, Latin America, North America, Africa and the Middle East.
"We are very pleased with the results of our collaboration with BDO, who provided us with valuable insights and guidance on the financial aspects of the acquisition. Their expertise, agility and professionalism enabled us to complete the deal quickly and smoothly."
Olga Lund, CFO, CNX Therapeutics